| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CORT | Common Stock | Award | $15.1K | +456 | +0.63% | $33.10 | 73.2K | Sep 1, 2023 | Direct | F1, F2, F3 |
| transaction | CORT | Common Stock | Award | $0 | +456 | +0.62% | $0.00 | 73.6K | Sep 1, 2023 | Direct | F3, F4 |
| holding | CORT | Common Stock | 10K | Sep 1, 2023 | See Footnote | F5 | |||||
| holding | CORT | Common Stock | 10K | Sep 1, 2023 | See Footnote | F6 |
| Id | Content |
|---|---|
| F1 | The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on September 1, 2023. |
| F2 | In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. |
| F3 | Includes 922 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022, 1,460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, and 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
| F4 | Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. |
| F5 | Represents the shares held by Duckhill Capital, LLC of which the reporting person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. |
| F6 | Represents the shares held by Sean and Molly Maduck Living Trust of which the reporting person is a co-trustee. |
President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.